Activities of Linezolid against nontuberculous mycobacteria.
The activity of linezolid (Pfizer, USA) was tested by broth microdilution against 53 clinical isolates of non-tuberculous mycobacteria (NTM), including the common disease producing species Mycobacterium avium, M. intracellulare, M. fortuitum, M. chelonae and M. abscessus, obtained from western Turkey. The isolates of M. abscessus and M. intracellulare were the least susceptible, M. mucogenicum, M. gordonae and M. avium were the most susceptible to linezolid of the common species of NTM. Linezolid showed a variable sensitivity in all strains; therefore, each species and strain must be individually evaluated, and it is always advisable to perform in vitro sensitivity tests before using the drug for human therapy.
Cavusoglu
Cengiz
C
Ege University Medical Faculty, Department of Clinical Microbiology, Bornova, Izmir, Turkey. cengizc2003@yahoo.com
Soyler
Ilknur
I
Akinci
Pinar
P
D000081:Acetamides / Q000494:pharmacology*; D000890:Anti-Infective Agents / Q000494:pharmacology*; D023381:Endpoint Determination; D006801:Humans; D000069349:Linezolid; D008826:Microbial Sensitivity Tests; D009165:Mycobacterium Infections, Nontuberculous / Q000382:microbiology*; D009170:Nontuberculous Mycobacteria / Q000187:drug effects* / Q000254:growth & development; D023303:Oxazolidinones / Q000494:pharmacology*; D013045:Species Specificity; D014421:Turkey
D000081:Acetamides; D000890:Anti-Infective Agents; D023303:Oxazolidinones; D000069349:Linezolid